VIB and VUB researchers involved in Innovative Medicines Initiative that awards 30 Million Euro grant supporting research into novel tracer strategies for clinical imaging of immune cell dynamics.
The VIB Discovery Sciences team bridges the gap between academic research and product development. Translating novel targets, emerging from research of VIB research groups into promising projects of drug-development and agro-biotech innovations is its core business. And the team proves to be successful. Time to present this established track record through three novel collaboration models.
Our brains do not only contain neurons, but also a variety of immune cells that play an important role for its functioning. A team led by Dr. Kiavash Movahedi (VIB Center for Inflammation Research at VUB) has developed a comprehensive cell atlas of the brain's immune compartment. This revealed not only the striking diversity of brain macrophages, but also found microglia where they were not expected.
ONCURIOUS NV, a Belgium-based biotech company focusing on the development of innovative oncology treatments, today announces that it has reached principle agreement with VIB to acquire exclusive licences to a portfolio of five unique next generation immuno-oncology assets, based on seminal work originating from the VIB-KU Leuven labs of Massimiliano Mazzone and Gabriele Bergers, and from the VIB-VUB lab of Jo Van Ginderachter.
In the human body, so-called dendritic cells are responsible for activating our immune system. While researchers previously believed that tumors could repress these dendritic cells – blocking an adequate natural cancer defense mechanism – a new study has painted a more positive picture. A team led by prof. Jo Van Ginderachter (VIB-Vrije Universiteit Brussel) revealed that two immune response-stimulating dendritic cell types do exist within tumors. The scientists were able to isolate these cells and use them to “vaccinate” tumors, slowing tumor growth. This success could lead to innovative new cancer immunotherapies. The results of the study are published in the high-impact journal Nature Communications.
We are in 2016, an important year for macrophages (and macrophage researchers). It has been 100 years since the death of Elie Metchnikoff who discovered macrophages: the ideal opportunity to focus on macrophage research within VIB. We had a chat with Martin Guilliams (VIB-UGent), Jo Van Ginderachter (VIB-Vrije Universiteit Brussel) and Max Mazzone (VIB-KU Leuven).